A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This study is testing a new experimental drug called NXP900 to see how well it works against advanced solid tumors. It is a 'Phase 1' trial, which means researchers are primarily looking to find the safest dose of the medication for patients whose cancer has not responded to standard treatments.
This trial is for adults (18+) with advanced solid tumors, such as certain types of lung or kidney cancer, where standard treatments are no longer working. You must be active enough to perform daily tasks and have tumors that can be clearly tracked with medical scans like a CT or MRI.
You will receive the experimental drug NXP900 and be closely monitored by a team of doctors to see how your body reacts to the treatment. The goal is to figure out the right dosage and see if the drug successfully stops cancer cells from growing.
The study is currently recruiting volunteers at medical centers in Phoenix, Arizona; Denver, Colorado; and Jacksonville, Florida. If you are interested, your care team can help you determine if this trial is a good fit for your specific health situation.
- 1NXP900 is an experimental drug, meaning it is not yet approved by the FDA for general use.
- 2This study focuses on solid tumors that have spread or returned after previous treatments.
- 3Participation is voluntary and you will have a dedicated team monitoring your safety throughout the trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.